OncoBayes progressing OB-001 to tackle ADC resistance and TKI brain penetration

Privately held clinical-stage pharmaceutical company OncoBayes announced completion of preclinical work on OB-001. The company said the work demonstrates the product’s potential to address ADC resistance and another oncology need, but the article text is truncated and provides no efficacy data or further details.